TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16139581

Group type: EXPERIMENTAL
Intervention: Active vagus nerve stimulation (VNS) for 12 months
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sham vagus nerve stimulation (VNS) for 12 months
Number of subjects: 202
Study: 11930093

Group type: EXPERIMENTAL
Intervention: Intensive Medical Therapy (IMT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Enhanced Toilet Training (ETT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 87
Study: 9799346

Group type: EXPERIMENTAL
Intervention: Sestamibi
Number of subjects: 400

Group type: COMPARATOR
Intervention: Tetrofosmin
Number of subjects: 400
Study: 8746103

Group type: EXPERIMENTAL
Intervention: Calcium carbasalate+metoclopramide (CSC-METO)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Dihydroergotamine mesilate (DHE)
Number of subjects: 155
Study: 2565728

Group type: EXPERIMENTAL
Intervention: 20 mg WY-45,727
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 mg WY-45,727
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 150 mg WY-45,727
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 589917

Group type: EXPERIMENTAL
Intervention: Double contrast barium meal
Number of subjects: 206

Group type: COMPARATOR
Intervention: Single contrast barium meal
Number of subjects: 206
Study: 31189785

Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP) intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 28188086

Group type: EXPERIMENTAL
Intervention: Treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib daily)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib daily)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Both treatment groups (A and B)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Treatment group A
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Treatment group B
Number of subjects: 229
Study: 26776900

Group type: EXPERIMENTAL
Intervention: CPR video self-instruction materials
Number of subjects: 653

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 653
Study: 25068884

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL; 1.7 g·kg(‐1)·day(‐1) for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (corn flour)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL)
Number of subjects: 15
Study: 22946607

Group type: EXPERIMENTAL
Intervention: Web-based intervention for caregivers (CGs)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Minimal support with individualized access to relevant online information (Control)
Number of subjects: 32
Study: 19721045

Group type: EXPERIMENTAL
Intervention: SPECT-CT imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: CT and bone scanning together
Number of subjects: 20
Study: 17284630

Group type: EXPERIMENTAL
Intervention: Selenomethionine 200 microg/d (group S1)
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Placebo (group S0)
Number of subjects: 2143

Group type: COMPARATOR
Intervention: Control group (TPOAb(-) age-matched women, group C)
Number of subjects: 2143
Study: 15510897

Group type: EXPERIMENTAL
Intervention: Alprazolam 3 x 0.5 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diazepam 3 x 2 mg
Number of subjects: 45
Study: 11479694

Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 levels in lung cancer patients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 levels in squamous cell and adenocarcinoma varieties
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 specificity and sensitivity
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 sensitivity for NSCLC
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 sensitivity in advanced stages of squamous cell lung cancer
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 levels after treatment in NSCLC patients
Number of subjects: 69
Study: 9916589

Group type: EXPERIMENTAL
Intervention: Extraperitoneal laparoscopic repair (TEP)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Mesh-plug hernioplasty
Number of subjects: 292

Group type: COMPARATOR
Intervention: Open-surgery group
Number of subjects: 292
Study: 8303945

Group type: EXPERIMENTAL
Intervention: Lederle/Takeda acellular pertussis component diphtheria‐tetanus‐pertussis vaccine (APDT)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Lederle whole‐cell pertussis component diphtheria‐tetanus‐pertussis vaccine (DTP)
Number of subjects: 149
Study: 2498507

Group type: EXPERIMENTAL
Intervention: Intralesional recombinant tumor necrosis factor-alpha (rTNF) at a recommended dose of 25 micrograms/m2
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30296436

Group type: EXPERIMENTAL
Intervention: Thermal ablation of the post-EMR mucosal defect margin (n = 210)
Number of subjects: 390

Group type: COMPARATOR
Intervention: No additional treatment (controls, n = 206)
Number of subjects: 390
Study: 27761981

Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate of 34 mmol/L
Number of subjects: 93

Group type: COMPARATOR
Intervention: Dialysate bicarbonate of 30 mmol/L
Number of subjects: 93
Study: 25005172

Group type: EXPERIMENTAL
Intervention: Life Review (LR) intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Active Control (AC) group (media workshop)
Number of subjects: 55
Study: 24456438

Group type: EXPERIMENTAL
Intervention: Prophylactic single-dose antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged course of antibiotics
Number of subjects: 0
Study: 22108776

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) during tuberculosis treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Efavirenz (EFV) off tuberculosis treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Slow metabolizers with tuberculosis treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Slow metabolizers without tuberculosis treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall effect of tuberculosis treatment on EFV clearance
Number of subjects: 58
Study: 19542314

Group type: EXPERIMENTAL
Intervention: Semiautomated methods
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fully automated method
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 17582145

Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 177

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study: 15837406

Group type: EXPERIMENTAL
Intervention: Patients with diffuse FIL (n=40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy control group (n=50)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between patients and control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with FIL
Number of subjects: 40
Study: 11874228

Group type: EXPERIMENTAL
Intervention: 10‐minute, 3 times per week, jumping program
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 10077258

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no chewing gum)
Number of subjects: 102
Study: 8838387

Group type: EXPERIMENTAL
Intervention: 40 trials of training on the rotary pursuit task
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80 trials of training on the rotary pursuit task
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 120 trials of training on the rotary pursuit task
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Retention tests conducted 20 min, 2 days, 7 days, and 37 days after practice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AD patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy older adults
Number of subjects: 24
Study: 1911021

Group type: EXPERIMENTAL
Intervention: 0.08% bupivacaine 8 ml
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Isotonic saline 8 ml
Number of subjects: 3

Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 3
Study: 6811766

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Megavoltage radiation therapy
Number of subjects: 97
Study: 30929060

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not provided)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Higher plasma BDNF levels
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Baseline BDNF exon IV promoter and p11 gene methylation status
Number of subjects: 173
Study: 31587995

Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram/day in addition to structured psychosocial intervention (PSI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo in addition to structured psychosocial intervention (PSI)
Number of subjects: 0
Study: 27987385

Group type: EXPERIMENTAL
Intervention: MICA mismatched HLA 10/10 donors
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: MICA mismatches
Number of subjects: 713

Group type: COMPARATOR
Intervention: MICA polymorphism (MICA-129)
Number of subjects: 713
Study: 25499548

Group type: EXPERIMENTAL
Intervention: Physical activity counselling programme (12 weeks)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 155
Study: 23447850

Group type: EXPERIMENTAL
Intervention: Night-vision goggles (NVG)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard helmet mockup (control)
Number of subjects: 5
Study: 22137082

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 19846844

Group type: EXPERIMENTAL
Intervention: 15 microg of nonadjuvanted vaccine
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: 30 microg of vaccine (with or without adjuvant)
Number of subjects: 2200

Group type: EXPERIMENTAL
Intervention: Vaccine without adjuvant
Number of subjects: 2200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2200
Study: 16907966

Group type: EXPERIMENTAL
Intervention: Isoflavone-enriched cereal bars (50 mg isoflavones/day; genistein to daidzein ratio 2:1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-isoflavone-enriched control bars
Number of subjects: 34
Study: 15109513

Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Citalopram 20 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11717605

Group type: EXPERIMENTAL
Intervention: COER verapamil 180 to 540 mg once daily in the evening for up to 10 weeks
Number of subjects: 1999

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1999

Group type: COMPARATOR
Intervention: Active comparator agent
Number of subjects: 1999
Study: 9553866

Group type: EXPERIMENTAL
Intervention: 0.1% ketorolac tromethamine oral rinse, twice daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 7894000

Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral alfacalcidol (4 micrograms, thrice-weekly for 6 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous alfacalcidol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral alfacalcidol
Number of subjects: 16
Study: 2449022

Group type: EXPERIMENTAL
Intervention: Aluminium chloride hexahydrate 25% in ethanol
Number of subjects: 30
Study: 31646727

Group type: EXPERIMENTAL
Intervention: Dulaglutide device
Number of subjects: 310
Study: 29602430

Group type: EXPERIMENTAL
Intervention: Health game Fume
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Non-gamified website
Number of subjects: 151

Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 151
Study: 28407264

Group type: EXPERIMENTAL
Intervention: Interval training (3 separate 30-minute sessions)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Massed training (1 single 90-minute session)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (Interval and Massed)
Number of subjects: 14
Study: 26513991

Group type: EXPERIMENTAL
Intervention: Chinese traditional treatment after routine treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 88
Study: 23884027

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT) for more than 10 years (group A)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT) for 3 to 10 years (group B)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 250
Study: 22010779

Group type: EXPERIMENTAL
Intervention: MBSR course (8-week mindfulness-based stress reduction course)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 19240655

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) - 17beta‐estradiol (1 mg) with cyclic micronized progesterone (200 mg) for 10 days per month
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16717034

Group type: EXPERIMENTAL
Intervention: Allyl amyl glycolate in 1:3 diethyl phthalate:ethanol at 2.0% concentration
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Allyl (cyclohexyloxy)acetate in 1:3 diethyl phthalate:ethanol at 2.0% concentration
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Allyl phenoxyacetate in 1:3 diethyl phthalate:ethanol at 2.0% concentration
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Allyl amyl glycolate in diethyl phthalate vehicle at 2.0% concentration
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Allyl (cyclohexyloxy)acetate in diethyl phthalate vehicle at 2.0% concentration
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Allyl phenoxyacetate in diethyl phthalate vehicle at 2.0% concentration
Number of subjects: 129
Study: 15538120

Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP) + Lithium (Li) or Divalproex (DVP)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo (PBO) + Lithium (Li) or Divalproex (DVP)
Number of subjects: 402
Study: 11379840

Group type: EXPERIMENTAL
Intervention: Admission QWB subscales for physical and social activity
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Benchmark model including age at first depression, admission BDI score, and melancholia
Number of subjects: 59
Study: 9403359

Group type: EXPERIMENTAL
Intervention: Methylsergide and Propranolol (antagonists at 5-HT receptors)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Ergotamine and Sumatriptan (5-HT1 agonists)
Number of subjects: 390
Study: 8124228

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 2459989

Group type: EXPERIMENTAL
Intervention: Aprotinin (2, 3.5, and 5 million KIU)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 40
Study: 30318743

Group type: EXPERIMENTAL
Intervention: HNRMS survivors
Number of subjects: 65
Study: 28855225

Group type: EXPERIMENTAL
Intervention: High fiber from diet (HFD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High fiber from supplement (HFS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual fiber (UF)
Number of subjects: 19
Study: 25970050

Group type: EXPERIMENTAL
Intervention: TAS-102
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 22986445

Group type: EXPERIMENTAL
Intervention: High-speed treadmill with body weight support system (HST)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Standard treadmill (ST) without body weight support system
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (NT)
Number of subjects: 32
Study: 21531089

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 189
Study: 18579898

Group type: EXPERIMENTAL
Intervention: Structured exercise (STEX)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (PASS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 61
Study: 16783060

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (standard chemotherapy)
Number of subjects: 140
Study: 15144931

Group type: EXPERIMENTAL
Intervention: Carvedilol (maximum dose of 25 mg bid)
Number of subjects: 1959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959
Study: 11056096

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 8886633

Group type: COMPARATOR
Intervention: Sodium tetradecyl sulfate (1.5% STS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hypertonic glucose water (50% GW)
Number of subjects: 51
Study: 1642222

Group type: EXPERIMENTAL
Intervention: Ranitidine plus enteric‐coated charcoal (four tablets daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine plus bismuth (30 ml Pepto‐Bismol four times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine alone (300 mg at bedtime)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg at bedtime) with all regimens
Number of subjects: 12
Study: 6138315

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg orally)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg orally)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30690653

Group type: EXPERIMENTAL
Intervention: Kinect-based Kaimai-style Qigong exercise
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (waitlisted)
Number of subjects: 55
Study: 27323775

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH; T core 33°C‐34°C)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normothermia (NT; T core 36°C‐37°C)
Number of subjects: 13
Study: 26012788

Group type: EXPERIMENTAL
Intervention: Interferential therapy (effective stimulation)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (sham stimulation)
Number of subjects: 200
Study: 24238769

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 12
Study: 21206386

Group type: EXPERIMENTAL
Intervention: GEMOX (gemcitabine 1,000 mg/m on days 1 and 8 followed by oxaliplatin 130 mg/m on day 1 every 3 weeks)
Number of subjects: 371

Group type: COMPARATOR
Intervention: PCb (paclitaxel 225 mg/m followed by carboplatin AUC = 6 on day 1 every 3 weeks)
Number of subjects: 371
Study: 19036535

Group type: EXPERIMENTAL
Intervention: Marijuana prevention program
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Parental marijuana use
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Parental aggression
Number of subjects: 257
Study: 17466657

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (12.5-62.5 mg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 15039515

Group type: EXPERIMENTAL
Intervention: Acetylcarnitine (2 g/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propionylcarnitine (2 g/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetylcarnitine + Propionylcarnitine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propionylcarnitine
Number of subjects: 30
Study: 11478511

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 80
Study: 9683394

Group type: EXPERIMENTAL
Intervention: Lecithin treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sunflower oil treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Frozen yoghurt (control)
Number of subjects: 20
Study: 7849232

Group type: EXPERIMENTAL
Intervention: Cefoperazone (1 g administered intravenously over 3-5 min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: GSP and MGEC tests
Number of subjects: 27
Study: 3154472

Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 369

Group type: COMPARATOR
Intervention: AZ (Control)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: T-cell antibody positive cases
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Cold B-cell positive cases
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: AZ and local graft irradiation
Number of subjects: 369
Study: 30956039

Group type: EXPERIMENTAL
Intervention: Radical surgery (RS)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Local excision (LE)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Wait-and-see (WS)
Number of subjects: 169
Study: 28572281

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus only
Number of subjects: 3044

Group type: EXPERIMENTAL
Intervention: Both METS and Diabetes Mellitus
Number of subjects: 3044

Group type: COMPARATOR
Intervention: Neither METS nor DM
Number of subjects: 3044

Group type: COMPARATOR
Intervention: METS only
Number of subjects: 3044
Study: 25236353

Group type: EXPERIMENTAL
Intervention: 7T MRI exposure
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mock scanner with no magnetic field
Number of subjects: 44
Study: 23631804

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (50,000 IU weekly for 8 weeks and 50,000 IU monthly for 10 months)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 22151921

Group type: EXPERIMENTAL
Intervention: Gluteal intramuscular corticosteroid injection
Number of subjects: 135

Group type: COMPARATOR
Intervention: Gluteal intramuscular placebo (saline) injection
Number of subjects: 135
Study: 19673352

Group type: EXPERIMENTAL
Intervention: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for three days (Group B)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for five days (Group C)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No oral antimicrobial administration (Group A)
Number of subjects: 3